// App-Quantinova.ai

364 : Validation of human osteoclast cultures for studying the mode-of-action and identification of new compounds with the potential of inhibiting the vicious cycle in osteolytic bone metastases

Researchers

Presenter

  • Jenni Bernoulli

Principal Investigators

  • Jussi M. Halleen

  • Mari I. Suominen

  • Johanna Tuomela

  • Jukka Rissanen

  • Katja M. Fagerlund

Medical Centers

  • Pharmatest Services Ltd, Turku, Finland.

  • Univ. of Turku, Turku, Finland.

Locations

  • Finland

Companies

  • Pharmatest Services

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bone metastases

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 34

  • Colony stimulating factor 1

  • Receptor activator of nuclear factor kappa-Β ligand

Drug/Treatment

  • MK-0822

  • Denosumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved